SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$821M
Q3 2020
Positions
27
Filings on Record
15
2019–present window
Filed
Nov 16, 2020
original filing

Summary

Consonance Capital Management LP reported $821M in U.S.-listed holdings across 27 positions for Q3 2020.

Its largest position, MGNX, represents 11.5% of the portfolio.

Compared with Q2 2020, the fund opened 10 new positions and exited 15.

Portfolio Metrics

Turnover
+15.0%
vs prior filed quarter
Top-10 Concentration
+68.0%
share of reported value
Largest Position
+11.5%
Macrogenics
New / Exited
10 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 59.4%Other: 40.6%
  • Common Stock · 59.4% · $488M
  • Other · 40.6% · $333M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PTGXPROTAGONIST THERAPEUTICS INCNEW+2.37M2.37M+$46M$46M
TCR2 THERAPEUTICS INCNEW+1.51M1.51M+$31M$31M
HRTXHERON THERAPEUTICS INCNEW+2.01M2.01M+$30M$30M
SPRINGWORKS THERAPEUTICS INCNEW+602.7K602.7K+$29M$29M
MOLECULAR TEMPLATES INCNEW+1.74M1.74M+$19M$19M
CASI PHARMACEUTICALS INCNEW+6.56M6.56M+$10M$10M
ATNMACTINIUM PHARMACEUTICALS INCNEW+793.2K793.2K+$8M$8M
DEERFIELD HEALTHCARE TECH ACNEW+250.0K250.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

27 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MGNXMACROGENICS INChistory →COM11.50%$94M3.75M
2GNMKGENMARK DIAGNOSTICS INChistory →COM9.17%$75M5.30M
3MERSANA THERAPEUTICS INCCOM7.87%$65M3.47M
4ATARA BIOTHERAPEUTICS INCCOM7.40%$61M4.69M
5KDMNKADMON HLDGS INChistory →COM6.69%$55M14.01M
6APTOSE BIOSCIENCES INCCOM NEW5.84%$48M7.99M
7PTGXPROTAGONIST THERAPEUTICS INChistory →COM5.64%$46M2.37M
8COMPUGEN LTDORD5.22%$43M2.64M
9KINIKSA PHARMACEUTICALS LTDCOM CL A4.43%$36M2.37M
10APREA THERAPEUTICS INCCOM4.28%$35M1.46M
11LIMINAL BIOSCIENCES INCCOM4.18%$34M3.08M
12ASSEMBLY BIOSCIENCES INCCOM3.95%$32M1.97M
13TCR2 THERAPEUTICS INCCOM3.74%$31M1.51M
14HRTXHERON THERAPEUTICS INChistory →COM3.62%$30M2.01M
15SPRINGWORKS THERAPEUTICS INCCOM3.50%$29M602.7K
16IVERIC BIO INCCOM2.64%$22M3.84M
17MOLECULAR TEMPLATES INCCOM2.31%$19M1.74M
18AXOVANT SCIENCES LTDCOM1.82%$15M3.24M
19STXSSTEREOTAXIS INChistory →COM NEW1.37%$11M3.14M
20CASI PHARMACEUTICALS INCCOM1.22%$10M6.56M
21ATNMACTINIUM PHARMACEUTICALS INCCOM0.94%$8M793.2K
22SOLENO THERAPEUTICS INCCOM NEW0.93%$8M3.04M
23OMEROMEROS CORPCOM0.60%$5M484.0K
24ADMAADMA BIOLOGICS INCCOM0.45%$4M1.56M
25DEERFIELD HEALTHCARE TECH ACUNIT 07/16/20250.32%$3M250.0K
26BCTG ACQUISITION CORPCOM0.23%$2M180.0K
27FS DEV CORPCOM CL A0.14%$1M100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.